---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-085474"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:44:58.714798+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Reports Q4 2025 Revenue of $15.7M, 216 New IBTROZI Patient Starts

## Summary
- IBTROZI (taletrectinib) launched in June 2025; 432 new patient starts by end of Q4 2025, with 216 in Q4 alone.
- Entered exclusive licensing/collaboration with Eisai on Jan 11, 2026 for taletrectinib in Europe and other regions.
- Cash, equivalents, and marketable securities of $529.2M as of Dec 31, 2025.
- Net product revenue from IBTROZI: $15.7M in Q4 2025, $24.7M for full year 2025.
- Positive Phase 2 safusidenib results published; ORR 44%, 88% progression-free at 24 months in grade 2 IDH1-mutant glioma.

## SEC filing metadata
- accession: 0001193125-26-085474
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312526085474/0001193125-26-085474-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312526085474/d15383d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-085474
- JSON: https://secwatch.observer/filing/0001193125-26-085474.json
- Plain text: https://secwatch.observer/filing/0001193125-26-085474.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.